Fig. 2

Kaplan–Meier curves for progression-free survival. A Total population. B Subgroup by the subcategory of primary trastuzumab resistance. Subgroup A included patients who had progression during adjuvant trastuzumab; subgroup B included patients who had progression within 12 months of completing adjuvant trastuzumab; subgroup C included patients who had progression within 6 months after the initiation of first-line trastuzumab for advanced disease. C Subgroup by hormone receptor status